指南与共识头颈技术与安全PET

分化型甲状腺癌131I治疗中的争议、共识与协作:美国甲状腺协会、欧洲核医学协会、核医学与分子影像学会及欧洲甲状腺协会的联合声明

Controversies, Consensus, and Collaboration in the Use of 131I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association.
指南 / 共识 · Thyroid · 2019-01-01

2015年美国甲状腺协会(ATA)指南中关于放射性碘(131I)诊断与治疗的建议引发核医学界异议,欧洲核医学协会与核医学与分子影像学会拒绝背书。四大协会召开两天会议,形成《马提尼克原则》九项原则,涉及131I辅助治疗指征、处方活度及难治性甲状腺癌定义与分类等。

要点

  • 九项原则明确131I治疗目标为残留消融、辅助治疗或已知病灶治疗。
  • 辅助治疗最佳给药活度无法从已发表文献中确定。
  • 当前难治性疾病的定义欠佳,不能作为是否推荐131I治疗的确定性标准。

核心结论

  • 会议形成九项《马提尼克原则》,强调跨学科协作,并指出131I辅助治疗最佳活度无法从文献确定、当前难治性定义欠佳。

研究设计与样本

  • 由美国甲状腺协会、欧洲核医学协会、核医学与分子影像学会及欧洲甲状腺协会各派高级领导和专家参加的两天互动会议。

诊断标准与关键数值

  • 131I治疗目标定义为残留消融、辅助治疗或已知疾病治疗。
  • 辅助治疗最佳给药活度无法从已发表文献中确定。
  • 当前难治性疾病的定义欠佳,不代表强制决定是否推荐131I治疗的确定性标准。

临床应用与阅片要点

  • 作者等认为131I治疗决策应评估术后疾病状态及临床病理分期之外的多个因素。

局限性

  • 辅助治疗最佳给药活度无法从已发表文献中确定。
  • 当前难治性疾病的定义欠佳,不代表强制决定是否推荐131I治疗的确定性标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Publication of the 2015 American Thyroid Association (ATA) management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer was met with disagreement by the extended nuclear medicine community with regard to some of the recommendations related to the diagnostic and therapeutic use of radioiodine (131I). Because of these concerns, the European Association of Nuclear Medicine and the Society of Nuclear Medicine and Molecular Imaging declined to endorse the ATA guidelines. As a result of these differences in opinion, patients and clinicians risk receiving conflicting advice with regard to several key thyroid cancer management issues.

SUMMARY: To address some of the differences in opinion and controversies associated with the therapeutic uses of 131I in differentiated thyroid cancer constructively, the ATA, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association each sent senior leadership and subject-matter experts to a two-day interactive meeting. The goals of this first meeting were to (i) formalize the dialogue and activities between the four societies; (ii) discuss indications for 131I adjuvant treatment; (iii) define the optimal prescribed activity of 131I for adjuvant treatment; and (iv) clarify the definition and classification of 131I-refractory thyroid cancer.

CONCLUSION: By fostering an open, productive, and evidence-based discussion, the Martinique meeting restored trust, confidence, and a sense of collegiality between individuals and organizations that are committed to optimal thyroid disease management. The result of this first meeting is a set of nine principles (The Martinique Principles) that (i) describe a commitment to proactive, purposeful, and inclusive interdisciplinary cooperation; (ii) define the goals of 131I therapy as remnant ablation, adjuvant treatment, or treatment of known disease; (iii) describe the importance of evaluating postoperative disease status and multiple other factors beyond clinicopathologic staging in 131I therapy decision making; (iv) recognize that the optimal administered activity of 131I adjuvant treatment cannot be definitely determined from the published literature; and (v) acknowledge that current definitions of 131I-refractory disease are suboptimal and do not represent definitive criteria to mandate whether 131I therapy should be recommended.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Tuttle RM, Ahuja S, Avram AM, et al. Controversies, Consensus, and Collaboration in the Use of 131I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid. 2019. PMID: 30900516. doi:10.1089/thy.2018.0597

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。